OCUL101 Neovascular AMD Phase II/III Trial
Summary
ClinicalTrials.gov registered Outlook Therapeutics' Phase II/III trial (NCT07520318) evaluating OCUL101 ophthalmic solution in treatment-naive subjects with neovascular age-related macular degeneration. The study will assess multiple endpoints including change from baseline in best-corrected visual acuity at 12 months.
What changed
Clinical trial NCT07520318 registered for OCUL101, an ophthalmic solution being evaluated for neovascular age-related macular degeneration. The Phase II/III study will enroll treatment-naive subjects to assess efficacy and safety endpoints.
Affected parties including clinical investigators, trial sponsors, and healthcare providers should note the trial is now publicly listed with enrollment eligibility criteria, locations, and study endpoints available for review.
What to do next
- Monitor ClinicalTrials.gov for updates to trial status and results
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.